View Financial HealthAristo Bio-Tech and Lifescience 配当と自社株買い配当金 基準チェック /36Aristo Bio-Tech and Lifescience配当を支払う会社であり、現在の利回りは0.55%で、収益によって十分にカバーされています。主要情報0.5%配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向6%最近の配当と自社株買いの更新お知らせ • Sep 24Aristo Bio-Tech and Lifescience Limited Approves Final Dividend for the Financial Year Ended March 31, 2024Aristo Bio-Tech and Lifescience Limited at its 19th Annual General Meeting held on September 20, 2024, approved to declare a final dividend of INR 0.4 per share (Rupees Forty Paisa only) per Equity share of INR 10 each for the financial year ended on March 31, 2024.Declared Dividend • Aug 30Dividend increased to ₹0.40Dividend of ₹0.40 is 60% higher than last year. Ex-date: 6th September 2024 Payment date: 20th October 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (26% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.すべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹110, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 82% over the past three years.Valuation Update With 7 Day Price Move • Jun 10Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹91.00, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 64% over the past three years.分析記事 • Jun 09Here's Why We Think Aristo Bio-Tech and Lifescience (NSE:ARISTO) Might Deserve Your Attention TodayThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹10.55 (vs ₹5.97 in FY 2025)Full year 2026 results: EPS: ₹10.55 (up from ₹5.97 in FY 2025). Revenue: ₹3.64b (up 14% from FY 2025). Net income: ₹71.8m (up 77% from FY 2025). Profit margin: 2.0% (up from 1.3% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 22Aristo Bio-Tech and Lifescience Limited to Report Second Half, 2026 Results on May 29, 2026Aristo Bio-Tech and Lifescience Limited announced that they will report second half, 2026 results on May 29, 2026Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹99.00, the stock trades at a trailing P/E ratio of 18.3x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 76% over the past three years.New Risk • Nov 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.0% Last year net profit margin: 1.8% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹834.0m market cap, or US$9.31m). Minor Risks High level of debt (79% net debt to equity). Share price has been volatile over the past 3 months (7.9% average weekly change). Profit margins are more than 30% lower than last year (1.0% net profit margin).お知らせ • Nov 13Aristo Bio-Tech and Lifescience Limited to Report First Half, 2026 Results on Nov 14, 2025Aristo Bio-Tech and Lifescience Limited announced that they will report first half, 2026 results on Nov 14, 2025Buy Or Sell Opportunity • Oct 15Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 8.0% to ₹135. The fair value is estimated to be ₹110, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%.Buy Or Sell Opportunity • Sep 30Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 1.9% to ₹133. The fair value is estimated to be ₹110, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%.分析記事 • Sep 18Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO) Soars 26% But It's A Story Of Risk Vs RewardAristo Bio-Tech and Lifescience Limited ( NSE:ARISTO ) shares have had a really impressive month, gaining 26% after a...Buy Or Sell Opportunity • Sep 12Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 20% to ₹136. The fair value is estimated to be ₹111, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%.Board Change • Sep 08Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. 2 independent directors (4 non-independent directors). Non- Executive Independent Director Rashmi Otavani was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Aug 18Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 08, 2025Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 08, 2025, at 15:00 Indian Standard Time.分析記事 • Jul 03Take Care Before Diving Into The Deep End On Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO)With a price-to-earnings (or "P/E") ratio of 21.8x Aristo Bio-Tech and Lifescience Limited ( NSE:ARISTO ) may be...Buy Or Sell Opportunity • Jun 02Now 18% undervaluedOver the last 90 days, the stock has risen 61% to ₹142. The fair value is estimated to be ₹172, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks High level of debt (51% net debt to equity). Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Market cap is less than US$100m (₹963.3m market cap, or US$11.3m).分析記事 • May 31Estimating The Intrinsic Value Of Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO)Key Insights Aristo Bio-Tech and Lifescience's estimated fair value is ₹172 based on 2 Stage Free Cash Flow to Equity...New Risk • May 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹844.2m (US$9.86m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (₹844.2m market cap, or US$9.86m). Minor Risk High level of debt (51% net debt to equity).Buy Or Sell Opportunity • May 16Now 24% undervaluedOver the last 90 days, the stock has risen 11% to ₹130. The fair value is estimated to be ₹172, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.Buy Or Sell Opportunity • Apr 25Now 21% undervaluedOver the last 90 days, the stock has risen 1.1% to ₹137. The fair value is estimated to be ₹172, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.Buy Or Sell Opportunity • Apr 07Now 24% undervaluedOver the last 90 days, the stock has risen 1.7% to ₹131. The fair value is estimated to be ₹174, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.分析記事 • Mar 27Do Aristo Bio-Tech and Lifescience's (NSE:ARISTO) Earnings Warrant Your Attention?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Valuation Update With 7 Day Price Move • Mar 26Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹110, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 24x in the Chemicals industry in India. Total returns to shareholders of 69% over the past year.Valuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹105, the stock trades at a trailing P/E ratio of 12.2x. Average trailing P/E is 25x in the Chemicals industry in India. Total returns to shareholders of 18% over the past year.分析記事 • Feb 12Is Aristo Bio-Tech and Lifescience (NSE:ARISTO) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Risk • Jan 14New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹837.4m (US$9.67m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$10m (₹837.4m market cap, or US$9.67m). Minor Risk High level of debt (51% net debt to equity).Board Change • Dec 18Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non- Executive Independent Director Rashmi Otavani was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Buy Or Sell Opportunity • Dec 03Now 22% undervaluedOver the last 90 days, the stock has risen 44% to ₹143. The fair value is estimated to be ₹182, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.Valuation Update With 7 Day Price Move • Nov 14Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹131, the stock trades at a trailing P/E ratio of 22.9x. Average trailing P/E is 33x in the Chemicals industry in India. Total returns to shareholders of 76% over the past year.分析記事 • Oct 30Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO) Doing What It Can To Lift SharesWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") above 32x, you may consider Aristo...Valuation Update With 7 Day Price Move • Oct 23Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹125, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 59% over the past year.お知らせ • Sep 24Aristo Bio-Tech and Lifescience Limited Approves Final Dividend for the Financial Year Ended March 31, 2024Aristo Bio-Tech and Lifescience Limited at its 19th Annual General Meeting held on September 20, 2024, approved to declare a final dividend of INR 0.4 per share (Rupees Forty Paisa only) per Equity share of INR 10 each for the financial year ended on March 31, 2024.New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Market cap is less than US$10m (₹722.6m market cap, or US$8.62m). Minor Risk Short dividend paying track record (1 year of continuous dividend payments).お知らせ • Aug 30Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 20, 2024Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 20, 2024, at 15:00 Indian Standard Time.Declared Dividend • Aug 30Dividend increased to ₹0.40Dividend of ₹0.40 is 60% higher than last year. Ex-date: 6th September 2024 Payment date: 20th October 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (26% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.分析記事 • Aug 22Is Aristo Bio-Tech and Lifescience (NSE:ARISTO) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...分析記事 • Jun 29Potential Upside For Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO) Not Without RiskWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") above 33x, you may consider Aristo...Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹90.35, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 54% over the past year.New Risk • May 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (13% average weekly change). High level of non-cash earnings (21% accrual ratio). Market cap is less than US$10m (₹539.5m market cap, or US$6.49m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Paying a dividend despite having no free cash flows.Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹73.70, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 22% over the past year.分析記事 • Mar 22If EPS Growth Is Important To You, Aristo Bio-Tech and Lifescience (NSE:ARISTO) Presents An OpportunityIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹68.50, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 22% over the past year.New Risk • Mar 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (21% accrual ratio). Market cap is less than US$10m (₹372.0m market cap, or US$4.49m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.9% average weekly change).Valuation Update With 7 Day Price Move • Mar 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹71.80, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 1.8% over the past year.Valuation Update With 7 Day Price Move • Feb 14Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹80.05, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 11% over the past year.Valuation Update With 7 Day Price Move • Jan 31Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹85.00, the stock trades at a trailing P/E ratio of 16.2x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 6.3% over the past year.New Risk • Oct 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). Share price has been highly volatile over the past 3 months (9.0% average weekly change). High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₹564.0m market cap, or US$6.77m).Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹69.55, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 22x in the Chemicals industry in India.New Risk • Jun 13New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₹382.3m market cap, or US$4.64m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.2% average weekly change).Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹64.00, the stock trades at a trailing P/E ratio of 30.1x. Average trailing P/E is 20x in the Chemicals industry in India.Valuation Update With 7 Day Price Move • Mar 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹70.75, the stock trades at a trailing P/E ratio of 33.2x. Average trailing P/E is 19x in the Chemicals industry in India.Reported Earnings • Jan 30Full year 2022 earnings released: EPS: ₹2.90 (vs ₹2.15 in FY 2021)Full year 2022 results: EPS: ₹2.90 (up from ₹2.15 in FY 2021). Revenue: ₹1.66b (flat on FY 2021). Net income: ₹14.5m (up 35% from FY 2021). Profit margin: 0.9% (up from 0.6% in FY 2021).Board Change • Jan 30Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Surendra Lakhawat was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.お知らせ • Jan 30Aristo Bio-Tech and Lifescience Limited has completed an IPO in the amount of INR 130.5216 million.Aristo Bio-Tech and Lifescience Limited has completed an IPO in the amount of INR 130.5216 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 860,800 Price\Range: INR 72 Discount Per Security: INR 5.1336 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 860,800 Price\Range: INR 72 Discount Per Security: INR 5.1336 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 91,200 Price\Range: INR 72 Discount Per Security: INR 5.1336 Transaction Features: Regulation S決済の安定と成長配当データの取得安定した配当: 配当金の支払いは安定していますが、 ARISTOが配当金を支払っている期間は 10 年未満です。増加する配当: ARISTOの配当金は増加していますが、同社は3年間しか配当金を支払っていません。配当利回り対市場Aristo Bio-Tech and Lifescience 配当利回り対市場ARISTO 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (ARISTO)0.5%市場下位25% (IN)0.3%市場トップ25% (IN)1.4%業界平均 (Chemicals)0.8%アナリスト予想 (ARISTO) (最長3年)n/a注目すべき配当: ARISTOの配当金 ( 0.55% ) はIndian市場の配当金支払者の下位 25% ( 0.29% ) よりも高くなっています。高配当: ARISTOの配当金 ( 0.55% ) はIndian市場の配当金支払者の上位 25% ( 1.44% ) と比較すると低いです。株主への利益配当収益カバレッジ: ARISTO の配当性向 (5.7%) は低いため、配当金の支払いは利益によって十分にカバーされます。株主配当金キャッシュフローカバレッジ: ARISTOは 現金配当性向 ( 7.4% ) が低いため、配当金の支払いはキャッシュフローによって完全にカバーされています。高配当企業の発掘7D1Y7D1Y7D1YIN 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/26 05:53終値2026/07/22 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aristo Bio-Tech and Lifescience Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Sep 24Aristo Bio-Tech and Lifescience Limited Approves Final Dividend for the Financial Year Ended March 31, 2024Aristo Bio-Tech and Lifescience Limited at its 19th Annual General Meeting held on September 20, 2024, approved to declare a final dividend of INR 0.4 per share (Rupees Forty Paisa only) per Equity share of INR 10 each for the financial year ended on March 31, 2024.
Declared Dividend • Aug 30Dividend increased to ₹0.40Dividend of ₹0.40 is 60% higher than last year. Ex-date: 6th September 2024 Payment date: 20th October 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (26% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.
Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹110, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 82% over the past three years.
Valuation Update With 7 Day Price Move • Jun 10Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹91.00, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 64% over the past three years.
分析記事 • Jun 09Here's Why We Think Aristo Bio-Tech and Lifescience (NSE:ARISTO) Might Deserve Your Attention TodayThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹10.55 (vs ₹5.97 in FY 2025)Full year 2026 results: EPS: ₹10.55 (up from ₹5.97 in FY 2025). Revenue: ₹3.64b (up 14% from FY 2025). Net income: ₹71.8m (up 77% from FY 2025). Profit margin: 2.0% (up from 1.3% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 22Aristo Bio-Tech and Lifescience Limited to Report Second Half, 2026 Results on May 29, 2026Aristo Bio-Tech and Lifescience Limited announced that they will report second half, 2026 results on May 29, 2026
Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹99.00, the stock trades at a trailing P/E ratio of 18.3x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 76% over the past three years.
New Risk • Nov 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.0% Last year net profit margin: 1.8% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹834.0m market cap, or US$9.31m). Minor Risks High level of debt (79% net debt to equity). Share price has been volatile over the past 3 months (7.9% average weekly change). Profit margins are more than 30% lower than last year (1.0% net profit margin).
お知らせ • Nov 13Aristo Bio-Tech and Lifescience Limited to Report First Half, 2026 Results on Nov 14, 2025Aristo Bio-Tech and Lifescience Limited announced that they will report first half, 2026 results on Nov 14, 2025
Buy Or Sell Opportunity • Oct 15Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 8.0% to ₹135. The fair value is estimated to be ₹110, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%.
Buy Or Sell Opportunity • Sep 30Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 1.9% to ₹133. The fair value is estimated to be ₹110, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%.
分析記事 • Sep 18Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO) Soars 26% But It's A Story Of Risk Vs RewardAristo Bio-Tech and Lifescience Limited ( NSE:ARISTO ) shares have had a really impressive month, gaining 26% after a...
Buy Or Sell Opportunity • Sep 12Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 20% to ₹136. The fair value is estimated to be ₹111, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%.
Board Change • Sep 08Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. 2 independent directors (4 non-independent directors). Non- Executive Independent Director Rashmi Otavani was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Aug 18Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 08, 2025Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 08, 2025, at 15:00 Indian Standard Time.
分析記事 • Jul 03Take Care Before Diving Into The Deep End On Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO)With a price-to-earnings (or "P/E") ratio of 21.8x Aristo Bio-Tech and Lifescience Limited ( NSE:ARISTO ) may be...
Buy Or Sell Opportunity • Jun 02Now 18% undervaluedOver the last 90 days, the stock has risen 61% to ₹142. The fair value is estimated to be ₹172, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.
New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks High level of debt (51% net debt to equity). Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Market cap is less than US$100m (₹963.3m market cap, or US$11.3m).
分析記事 • May 31Estimating The Intrinsic Value Of Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO)Key Insights Aristo Bio-Tech and Lifescience's estimated fair value is ₹172 based on 2 Stage Free Cash Flow to Equity...
New Risk • May 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹844.2m (US$9.86m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (₹844.2m market cap, or US$9.86m). Minor Risk High level of debt (51% net debt to equity).
Buy Or Sell Opportunity • May 16Now 24% undervaluedOver the last 90 days, the stock has risen 11% to ₹130. The fair value is estimated to be ₹172, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.
Buy Or Sell Opportunity • Apr 25Now 21% undervaluedOver the last 90 days, the stock has risen 1.1% to ₹137. The fair value is estimated to be ₹172, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.
Buy Or Sell Opportunity • Apr 07Now 24% undervaluedOver the last 90 days, the stock has risen 1.7% to ₹131. The fair value is estimated to be ₹174, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.
分析記事 • Mar 27Do Aristo Bio-Tech and Lifescience's (NSE:ARISTO) Earnings Warrant Your Attention?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Valuation Update With 7 Day Price Move • Mar 26Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹110, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 24x in the Chemicals industry in India. Total returns to shareholders of 69% over the past year.
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹105, the stock trades at a trailing P/E ratio of 12.2x. Average trailing P/E is 25x in the Chemicals industry in India. Total returns to shareholders of 18% over the past year.
分析記事 • Feb 12Is Aristo Bio-Tech and Lifescience (NSE:ARISTO) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Risk • Jan 14New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹837.4m (US$9.67m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$10m (₹837.4m market cap, or US$9.67m). Minor Risk High level of debt (51% net debt to equity).
Board Change • Dec 18Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non- Executive Independent Director Rashmi Otavani was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Buy Or Sell Opportunity • Dec 03Now 22% undervaluedOver the last 90 days, the stock has risen 44% to ₹143. The fair value is estimated to be ₹182, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.
Valuation Update With 7 Day Price Move • Nov 14Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹131, the stock trades at a trailing P/E ratio of 22.9x. Average trailing P/E is 33x in the Chemicals industry in India. Total returns to shareholders of 76% over the past year.
分析記事 • Oct 30Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO) Doing What It Can To Lift SharesWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") above 32x, you may consider Aristo...
Valuation Update With 7 Day Price Move • Oct 23Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹125, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 59% over the past year.
お知らせ • Sep 24Aristo Bio-Tech and Lifescience Limited Approves Final Dividend for the Financial Year Ended March 31, 2024Aristo Bio-Tech and Lifescience Limited at its 19th Annual General Meeting held on September 20, 2024, approved to declare a final dividend of INR 0.4 per share (Rupees Forty Paisa only) per Equity share of INR 10 each for the financial year ended on March 31, 2024.
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Market cap is less than US$10m (₹722.6m market cap, or US$8.62m). Minor Risk Short dividend paying track record (1 year of continuous dividend payments).
お知らせ • Aug 30Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 20, 2024Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 20, 2024, at 15:00 Indian Standard Time.
Declared Dividend • Aug 30Dividend increased to ₹0.40Dividend of ₹0.40 is 60% higher than last year. Ex-date: 6th September 2024 Payment date: 20th October 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (26% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.
分析記事 • Aug 22Is Aristo Bio-Tech and Lifescience (NSE:ARISTO) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
分析記事 • Jun 29Potential Upside For Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO) Not Without RiskWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") above 33x, you may consider Aristo...
Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹90.35, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 54% over the past year.
New Risk • May 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (13% average weekly change). High level of non-cash earnings (21% accrual ratio). Market cap is less than US$10m (₹539.5m market cap, or US$6.49m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Paying a dividend despite having no free cash flows.
Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹73.70, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 22% over the past year.
分析記事 • Mar 22If EPS Growth Is Important To You, Aristo Bio-Tech and Lifescience (NSE:ARISTO) Presents An OpportunityIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹68.50, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 22% over the past year.
New Risk • Mar 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (21% accrual ratio). Market cap is less than US$10m (₹372.0m market cap, or US$4.49m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.9% average weekly change).
Valuation Update With 7 Day Price Move • Mar 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹71.80, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 1.8% over the past year.
Valuation Update With 7 Day Price Move • Feb 14Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹80.05, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 11% over the past year.
Valuation Update With 7 Day Price Move • Jan 31Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹85.00, the stock trades at a trailing P/E ratio of 16.2x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 6.3% over the past year.
New Risk • Oct 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). Share price has been highly volatile over the past 3 months (9.0% average weekly change). High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₹564.0m market cap, or US$6.77m).
Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹69.55, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 22x in the Chemicals industry in India.
New Risk • Jun 13New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₹382.3m market cap, or US$4.64m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.2% average weekly change).
Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹64.00, the stock trades at a trailing P/E ratio of 30.1x. Average trailing P/E is 20x in the Chemicals industry in India.
Valuation Update With 7 Day Price Move • Mar 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹70.75, the stock trades at a trailing P/E ratio of 33.2x. Average trailing P/E is 19x in the Chemicals industry in India.
Reported Earnings • Jan 30Full year 2022 earnings released: EPS: ₹2.90 (vs ₹2.15 in FY 2021)Full year 2022 results: EPS: ₹2.90 (up from ₹2.15 in FY 2021). Revenue: ₹1.66b (flat on FY 2021). Net income: ₹14.5m (up 35% from FY 2021). Profit margin: 0.9% (up from 0.6% in FY 2021).
Board Change • Jan 30Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Surendra Lakhawat was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
お知らせ • Jan 30Aristo Bio-Tech and Lifescience Limited has completed an IPO in the amount of INR 130.5216 million.Aristo Bio-Tech and Lifescience Limited has completed an IPO in the amount of INR 130.5216 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 860,800 Price\Range: INR 72 Discount Per Security: INR 5.1336 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 860,800 Price\Range: INR 72 Discount Per Security: INR 5.1336 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 91,200 Price\Range: INR 72 Discount Per Security: INR 5.1336 Transaction Features: Regulation S